Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRAGUE-7: Upfront Abciximab in Cardiogenic Shock PCI
NCT00420030Phase 4Completed
- Sponsor
- Charles University
- Start
- Sep 2006
- Primary completion
- Jun 2009
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of abciximab in myocardial infarction (MI) and cardiogenic shock (2 arms), sponsored by Charles University. Primary endpoint: Combined end-point death/reinfarction/stroke/new renal failure at 30 days. Started Sep 2006; status: completed.
02
Drugs
abciximab
03
Conditions
myocardial infarction (MI)cardiogenic shock
Beyond the preview
Go deeper on NCT00420030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00420030.